Earnings Feed
Start Free
Home/Filings/4/0001127602-21-012256
4//SEC Filing

MERLO LARRY J 4

Accession 0001127602-21-012256

CIK 0000064803other
View on SEC.govCompany Profile

Filed

Mar 28, 8:00 PM ET

Accepted

Mar 29, 6:53 PM ET

Size

21.3 KB

Accession

0001127602-21-012256

Insider Transaction Report

Form 4
Period: 2021-03-26
CVS HEALTH CorpCVS
MERLO LARRY J
Executive Vice President
Transactions
  • Exercise/Conversion

    Common Stock

    2021-03-26$74.29/sh+271,347$20,158,369→ 794,675.941 total
  • Sale

    Common Stock

    2021-03-26$74.73/sh−270,650$20,225,675→ 524,025.941 total
  • Exercise/Conversion

    Stock Option

    2021-03-26−271,347→ 0 total
    Exercise: $74.29From: 2015-04-01Exp: 2021-04-01→ Common Stock (271,347 underlying)
Holdings

  • Common Stock

    (indirect: By Trust)
    406,633.497

  • Common Stock (restricted)

    40,701

  • ESOP Common Stock

    (indirect: By ESOP)
    7,548

  • Stock Option

    Exercise: $102.26From: 2016-04-01Exp: 2022-04-01→ Common Stock (273,929 underlying)
    273,929

  • Stock Option

    Exercise: $78.05From: 2018-04-03Exp: 2024-04-03→ Common Stock (338,105 underlying)
    338,105

  • Stock Option

    Exercise: $62.21From: 2019-04-01Exp: 2025-04-01→ Common Stock (394,091 underlying)
    394,091

  • Phantom Stock Credits

    Exercise: $1.00→ Common Stock (5,153.23 underlying)
    5,153.23

  • Stock Option

    Exercise: $104.82From: 2017-04-01Exp: 2023-04-01→ Common Stock (286,787 underlying)
    286,787

  • Stock Option

    Exercise: $58.34From: 2021-04-01Exp: 2030-04-01→ Common Stock (478,711 underlying)
    478,711

  • Stock Unit

    688,685.988

  • Stock Option

    Exercise: $54.19From: 2020-04-01Exp: 2029-04-01→ Common Stock (545,419 underlying)
    545,419
Footnotes (13)
  • [F1]All sales were effected pursuant to a Rule 10b5-1 Plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the Reporting Person retaining all remaining shares.
  • [F10]Option became exercisable in four equal annual installments, commencing 4/1/2019.
  • [F11]Option became exercisable in four equal annual installments, commencing 4/1/2020.
  • [F12]The number of shares subject to the option were calculated using a 30-day average price.
  • [F13]Option becomes exercisable in four equal annual installments, commencing 4/1/2021.
  • [F2]Represents weighted average sale prices for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $74.49 and $75.73 per share.
  • [F3]Option became exercisable in four equal annual installments, commencing 4/1/2015.
  • [F4]Each share credit is equivalent to one share; 1-for-1 conversion.
  • [F5]Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  • [F6]Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  • [F7]Option became exercisable in four equal annual installments, commencing 4/1/2016.
  • [F8]Option became exercisable in four equal annual installments, commencing 4/1/2017.
  • [F9]Option became exercisable in four equal annual installments, commencing 4/3/2018.

Documents

1 file

Issuer

CVS HEALTH Corp

CIK 0000064803

→
Entity typeother

Related Parties

1
  • filerCIK 0001194413

Filing Metadata

Form type
4
Filed
Mar 28, 8:00 PM ET
Accepted
Mar 29, 6:53 PM ET
Size
21.3 KB
View on SEC.gov